Skip to content

Interest Income at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$229M-31.0%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$23.4M-15.2%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$1.19M+51.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$6.25M+16.0%
Roivant Sciences logo
Roivant SciencesROIV
$41.18M-24.6%
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue--100%
Operating income-$112.3M-54.4%
Net income-$102.3M-57.3%
EPS (diluted)-$1.17-41.0%

Balance sheet

See full
Cash & equivalents$545.9M+368%
Total debt$7.5M-13.6%
Total equity$1.3B+90.0%
Total assets$1.4B+86.6%

Cash flow

See full
Operating cash flow-$88.9M-44.2%
CapEx$133.0K+209%
Free cash flow-$89.0M-44.3%

Valuation

See full
Market cap$5.11B+116%

Profitability

See full
Operating margin-4,974.3%
Net margin-4,612.1%
FCF margin-3,732.2%

Returns & leverage

See full
Return on equity-37.5%+8.7pp
Debt / equity0.0×
Current ratio27.8×+10.1×

Where this comes from

Reported directly by Xenon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xenon Pharmaceuticals's interest income?
Xenon Pharmaceuticals (XENE) reported interest income of $6.91M in Q1 2026.
How has Xenon Pharmaceuticals's interest income changed year-over-year?
Xenon Pharmaceuticals's interest income decreased by 14.5% year-over-year, from $8.08M to $6.91M.
What is the long-term trend for Xenon Pharmaceuticals's interest income?
Over 4 years (2021 to 2025), Xenon Pharmaceuticals's interest income has grown at a 175.5% compound annual growth rate (CAGR), from $466K to $26.83M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.